Regeneron Pharmaceuticals, Inc. (REGN) Receives Positive Rating from Leerink Swann
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “positive” rating reiterated by stock analysts at Leerink Swann in a note issued to investors on Tuesday, The Fly reports. They currently have a $552.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $580.00. Leerink Swann’s price objective points to a potential upside of 16.32% from the stock’s current price.
Other analysts also recently issued research reports about the stock. UBS AG set a $489.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday, May 5th. Canaccord Genuity set a $522.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Monday. BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a report on Monday, May 15th. Piper Jaffray Companies increased their price objective on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an “overweight” rating in a report on Tuesday, June 20th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $472.00 price objective (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $488.23.
Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 474.54 on Tuesday. The stock has a market cap of $50.32 billion, a price-to-earnings ratio of 47.61 and a beta of 1.66. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $543.55. The company has a 50-day moving average price of $494.31 and a 200 day moving average price of $428.60.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.82 EPS. On average, analysts expect that Regeneron Pharmaceuticals will post $14.84 earnings per share for the current year.
In other Regeneron Pharmaceuticals news, EVP Neil Stahl sold 8,306 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total transaction of $4,423,360.30. Following the completion of the transaction, the executive vice president now owns 43,950 shares in the company, valued at $23,405,572.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Sanofi bought 136,050 shares of the business’s stock in a transaction on Friday, June 2nd. The shares were acquired at an average price of $478.17 per share, with a total value of $65,055,028.50. The disclosure for this purchase can be found here. In the last three months, insiders have sold 56,922 shares of company stock worth $27,383,105. 10.40% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in the company. Korea Investment CORP boosted its position in shares of Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 206 shares during the last quarter. Fieldpoint Private Securities LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $130,000. Sterling Investment Advisors Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 11.2% in the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 28 shares during the last quarter. FNY Managed Accounts LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth about $140,000. Finally, FNY Partners Fund LP boosted its position in shares of Regeneron Pharmaceuticals by 200.0% in the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 200 shares during the last quarter. Institutional investors own 67.16% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.